Luxembourg, 5 March 2026
The Jean Boulle Group (“the Group”) is pleased to note the announcement made today by Medtech device company VDyne (“the Company”) that Mike Buck has been appointed Chief Executive Officer (“CEO”) and Chairman of the Company. VDyne is developing its innovative heart valve technology which is a transcatheter tricuspid valve replacement (TTVR) system for the treatment of tricuspid regurgitation, a debilitating condition that impacts the general health and quality of life of a significant portion of the patient population.
With more than 30 years of experience in leading cardiovascular medical technologies through advanced clinical studies, organisational growth and licensing milestones, Mike Buck has the specific relevant expertise to lead the next phase of VDyne’s Transcatheter Tricuspid Valve Replacement programme.
Since introducing the Company’s final design into the clinical setting in November 2023, VDYNE has treated more than 100 cases across 15 countries under the VISTA-US Study, the VISTA-Global Study and other protocols. VDYNE is presently advancing its registrational study to support CE Marking and with the benefit of having been previously granted U.S. Food & Drug Administration (FDA) FDA Breakthrough Device Designation.
VDyne is the second heart valve technology discovered and founded by a scientific team assembled by the Group’s Jean Boulle Medtech Ltd. The first company was Tendyne™, acquired by Abbott Laboratories (NYSE: ABT) for US$250 million, supplemented by an additional US$150 million upon regulatory milestones. Post-acquisition, Tendyne™ received CE Mark approval from the European Union in January 2020 and approval for use in US patients from the Food and Drug Administration (FDA) in May 2025.
Commenting on the announcement, Mr Jean-Raymond Boulle, Chairman and CEO of the Jean Boulle Group said:
“I am delighted that Mike Buck has joined Vdyne as Chief Executive Officer and Chairman to lead the Company through the next stages of its TTVR programme and assess its long term optionality given its strong scientific foundations. The team’s inspiring work in discovering and scaling this innovative technology in such a competitive industry has been the bedrock of VDyne’s success to date, which will continue to gain momentum under Mike’s leadership.”
The announcement below was issued today by VDyne:
PRESS RELEASE
VDyne Appoints Mike Buck as Chairman and CEO to Lead Next Phase of its TTVR Program
Maple Grove, Minnesota, March 5, 2026 – VDyne Inc. (“VDyne”), a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation, today announced the appointment of Mike Buck as Chairman and Chief Executive Officer.
Mr. Buck brings more than 30 years of leadership experience in cardiovascular medical technology. Most recently, he served as Chief Executive Officer of Verge Medical and previously was Founder and Chief Executive Officer of TRUVIC Medical (acquired by Imperative Care). Earlier in his career, he served as President of Cardinal Health’s Medical Products Division and held senior leadership roles at Abbott, including Corporate Vice President and global commercial leader for Abbott’s Vascular business, as well as leading Abbott’s global Licensing and Acquisitions function.
VDyne has conducted clinical studies across 15 countries, with more than 100 successful TTVR procedures to date. The Company has received FDA Breakthrough Device designation and is advancing toward CE Mark and initiation of its U.S. pivotal clinical study, positioning VDyne among companies advancing next-generation TTVR therapies.
“VDyne has built a strong clinical foundation, and the opportunity to improve the lives of patients with tricuspid regurgitation is significant. I look forward to working alongside this team as we advance the technology and continue building the clinical evidence behind it,” said Mike Buck.
“Mike brings deep experience in structural heart and a proven ability to build and lead strong teams. As VDyne further advances its clinical programs, his leadership will be critical in guiding the company through its next phase,” said Dr. Greg Pearl, VDyne Board Member.
For more information, please contact:
VDyne: please email investor@vdyne.com or visit https://www.vdyne.com
Michael Oke +44 7834 368299
Khushi Hunt +44 7724 637405
+44 02078 321 0000
About Jean Boulle Group
The Group is principally active in sectors including medical technology, therapeutics, natural resources, agriculture, energy, luxury and philanthropy. Since its foundation by Jean-Raymond Boulle the Group has completed transactions worth more than US$5 billion and successfully listed investee companies on the following stock exchanges: AIM (England), TSX (Canada), ASX (Australia) and SEM (Mauritius). Its investments span early-stage private funding for innovative technologies through to acquisitions, special situations and strategic investments in publicly traded companies. The Group often co-invests alongside state investment and pension funds and uses its specific industry knowledge to discover, evaluate and develop new enterprises.
About Jean Boulle Medtech
Jean Boulle Medtech Ltd. (“JBM”) has a uniquely successful record of developing innovative transcatheter valve implant devices for use in cardiology. In 2021 VDyne closed a US$21 million, heavily subscribed Series C financing led by JBM. Subsequently, VDYNE received a further cash investment of approximately US$6.5 million from JBM and US$47 million cash investment from a new major strategic industry investor in its proprietary VDyne technology. JBM was the founding investor of Tendyne Holdings, Inc. which developed the first and most successful Transcatheter Mitral Valve Implant in existence today.
About VDyne Inc.
VDyne Inc. is a privately held medical device company based in Maple Grove, Minnesota, developing a transcatheter tricuspid valve replacement (TTVR) system for the treatment of tricuspid regurgitation.
VDyne’s TTVR system is currently under clinical investigation and is not approved for commercial sale in the United States or any other jurisdiction.